Esperion Therapeutics Inc logo

ESPR - Esperion Therapeutics Inc Share Price

$33.69 0.2  0.6%

Last Trade - 12/08/20

Mid Cap
Market Cap £708.6m
Enterprise Value £588.1m
Revenue £3.67m
Position in Universe 2438th / 6376
Unlock ESPR Revenue
Relative Strength (%)
1m -38.4%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -56.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 148.4 240.9 224.2
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Esperion Therapeutics Inc revenues increased 46% to $214.1M. Net income increased 40% to $46.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by General and administrative increase from $25.7M to $89.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ESPR
Graphical History


ESPR Revenue Unlock ESPR Revenue

Net Income

ESPR Net Income Unlock ESPR Revenue

Normalised EPS

ESPR Normalised EPS Unlock ESPR Revenue

PE Ratio Range

ESPR PE Ratio Range Unlock ESPR Revenue

Dividend Yield Range

ESPR Dividend Yield Range Unlock ESPR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ESPR EPS Forecasts Unlock ESPR Revenue
Profile Summary

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated January 22, 2008
Public Since June 24, 2013
No. of Shareholders: 12
No. of Employees: 193
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 27,617,431
Free Float (0.0%)
Eligible for
ESPR Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ESPR
Upcoming Events for ESPR
Wednesday 4th November, 2020 Estimate
Q3 2020 Esperion Therapeutics Inc Earnings Release
Frequently Asked Questions for Esperion Therapeutics Inc
What is the Esperion Therapeutics Inc share price?

As of 12/08/20, shares in Esperion Therapeutics Inc are trading at $33.69, giving the company a market capitalisation of £708.6m. This share price information is delayed by 15 minutes.

How has the Esperion Therapeutics Inc share price performed this year?

Shares in Esperion Therapeutics Inc are currently trading at $33.69 and the price has moved by -9.49% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Esperion Therapeutics Inc price has moved by -21.18% over the past year.

What are the analyst and broker recommendations for Esperion Therapeutics Inc?

Of the analysts with advisory recommendations for Esperion Therapeutics Inc, there are there are currently 6 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Esperion Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Esperion Therapeutics Inc next release its financial results?

Esperion Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Esperion Therapeutics Inc dividend yield?

Esperion Therapeutics Inc does not currently pay a dividend.

Does Esperion Therapeutics Inc pay a dividend?

Esperion Therapeutics Inc does not currently pay a dividend.

When does Esperion Therapeutics Inc next pay dividends?

Esperion Therapeutics Inc does not currently pay a dividend.

How do I buy Esperion Therapeutics Inc shares?

To buy shares in Esperion Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Esperion Therapeutics Inc?

Shares in Esperion Therapeutics Inc are currently trading at $33.69, giving the company a market capitalisation of £708.6m.

Where are Esperion Therapeutics Inc shares listed? Where are Esperion Therapeutics Inc shares listed?

Here are the trading details for Esperion Therapeutics Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: ESPR
What kind of share is Esperion Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Esperion Therapeutics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Esperion Therapeutics Inc share price forecast 2020?

Shares in Esperion Therapeutics Inc are currently priced at $33.69. At that level they are trading at 0.161% discount to the analyst consensus target price of 0.00.

Analysts covering Esperion Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -5.18 for the next financial year.

How can I tell whether the Esperion Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Esperion Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -54.39%. At the current price of $33.69, shares in Esperion Therapeutics Inc are trading at -28.66% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Esperion Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Esperion Therapeutics Inc.

Who are the key directors of Esperion Therapeutics Inc?

Esperion Therapeutics Inc's management team is headed by:

Roger Newton - DRC
Timothy Mayleben - PRE
Antonio Gotto - IND
Nicole Vitullo - LED
Narendra Lalwani - EVP
Daniel Janney - IND
Scott Braunstein - IND
Jeffrey Berkowitz - DRC
Richard Bartram - CFO
Jay Shepard - DRC
Tracy Woody - DRC
Mark Glickman - OTH
Alan Fuhrman - IND
Ashley Hall - OTH
Who are the major shareholders of Esperion Therapeutics Inc?

Here are the top five shareholders of Esperion Therapeutics Inc based on the size of their shareholding:

Bellevue Asset Management AG Investment Advisor
Percentage owned: 18.11% (5.04m shares)
BB Biotech Fd Mutual Fund
Percentage owned: 13.47% (3.75m shares)
Meditor Capital Management Limited Hedge Fund
Percentage owned: 9.63% (2.68m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.91% (2.48m shares)
Pentwater Capital Management LP Hedge Fund
Percentage owned: 8.31% (2.31m shares)
Similar to ESPR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.